Developments in Viral Vector-Based Vaccines

Vaccines
Takehiro UraMasaru Shimada

Abstract

Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.

References

Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D Panicali, E Paoletti
Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·M MackettB Moss
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T R FlotteB J Carter
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y YangJ M Wilson
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·B DropulićP M Pitha
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·R W HerzogK A High
Apr 10, 1999·Journal of Virology·W XiaoJ M Wilson
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·R SchroersS Y Chen
Apr 20, 2002·Science·Zhixiong LiChristopher Baum
May 7, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Deborah J WatsonJohn H Wolfe
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Guang-Ping GaoJames M Wilson
Nov 13, 2002·Human Gene Therapy·Masashi UrabeRobert M Kotin
Oct 8, 2003·Current Drug Targets. Infectious Disorders·Gerd Sutter, Caroline Staib
May 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shawn M SumidaDan H Barouch
May 27, 2005·Human Gene Therapy·Barrie J Carter
Jun 25, 2005·Current Gene Therapy·Vivian W ChoiR Jude Samulski
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard HarropMiles W Carroll
Nov 17, 2006·The Journal of Infectious Diseases·Andrew T CatanzaroUNKNOWN Vaccine Research Center 006 Study Team
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Susannah I ThornhillAdrian J Thrasher

❮ Previous
Next ❯

Citations

Dec 17, 2015·Viruses·Qingyong NgJimmy Kwang
Apr 23, 2016·Human Vaccines & Immunotherapeutics·Chao Zhang, Dongming Zhou
Jul 8, 2016·Expert Review of Vaccines·Irina Isakova-SivakLarisa Rudenko
Sep 4, 2016·Expert Opinion on Drug Delivery·Marija ZaricLinda Sylvia Klavinskis
Nov 30, 2016·Molecular Phylogenetics and Evolution·Eva DadákováKristýna Hrazdilová
Jan 26, 2017·Expert Opinion on Therapeutic Patents·Jiwon ChoiYoung Bong Kim
Dec 7, 2016·The Journal of Infectious Diseases·Katrin Ramsauer, Frédéric Tangy
Jan 19, 2019·Critical Reviews in Biotechnology·Ana Clara MignaquiAndrés Wigdorovitz
Jan 3, 2019·Expert Review of Vaccines·Christiane GerkeFrédéric Tangy
Apr 25, 2019·Human Vaccines & Immunotherapeutics·Xinle Cui, Clifford M Snapper
Nov 7, 2019·International Journal of Molecular Sciences·Suryaji PatilAi-Rong Qian
Jun 23, 2016·PloS One·Sebastian P FuchsRonald C Desrosiers
May 13, 2020·Nanomedicine·Harald UnterwegerChristoph Alexiou
Sep 7, 2017·Archives of Pharmacal Research·Hyoung Jin Kim, Hong-Jin Kim
Jun 19, 2019·Current HIV Research·Mona Sadat LarijaniSeyed Mehdi Sadat
Dec 12, 2019·Frontiers in Veterinary Science·Piet A van Rijn
Feb 23, 2020·Vaccines·Joshua D DuncanJonathan K Ball
Jan 8, 2020·Proceedings of the National Academy of Sciences of the United States of America·Ahmet OzdilekFikri Y Avci
May 12, 2020·Frontiers in Microbiology·Longping V TseRalph S Baric
Aug 21, 2019·Frontiers in Microbiology·Chean Yeah YongWen Siang Tan
Dec 4, 2019·Expert Review of Vaccines·Iván Del Moral-Sánchez, Kwinten Sliepen
Aug 28, 2020·F1000Research·Wern Hann NgSuresh Mahalingam
Aug 18, 2020·Journal of Community Genetics·Rocio MaldonadoKirmo Wartiovaara
Jul 25, 2020·Expert Review of Anti-infective Therapy·Mohammad HeiatAmirhossein Sahebkar
May 26, 2017·Biomedicines·Shyambabu Chaurasiya, Susanne Warner
Sep 28, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fengliang LiuHaitao Hu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01705990

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Related Papers

Progress in Medical Virology. Fortschritte Der Medizinischen Virusforschung. Progrès En Virologie Médicale
J F Woodruff, J J Woodruff
Current Opinion in HIV and AIDS
Giuseppe PantaleoJim Tartaglia
© 2021 Meta ULC. All rights reserved